Mahadevan Vaikom S, Campbell Malcolm, McKeown Pascal P, Bayraktutan Ulvi
Division of Medicine and Therapeutics, Institute of Clinical Science, Queen's University Belfast, UK.
Cardiovasc Res. 2006 Oct 1;72(1):60-8. doi: 10.1016/j.cardiores.2006.06.022. Epub 2006 Jun 27.
This study investigated whether differences exist in atherogen-induced migratory behaviors and basal antioxidant enzyme capacity of vascular smooth muscle cells (VSMC) from human coronary (CA) and internal mammary (IMA) arteries.
Migration experiments were performed using the Dunn chemotaxis chamber. The prooxidant [NAD(P)H oxidase] and antioxidant [NOS, superoxide dismutase, catalase and glutathione peroxidase] enzyme activities were determined by specific assays.
Chemotaxis experiments revealed that while both sets of VSMC migrated towards platelet-derived growth factor-BB (1-50 ng/ml) and angiotensin II (1-50 nM), neither oxidized-LDL (ox-LDL, 25-100 microg/ml) nor native LDL (100 microg/ml) affected chemotaxis in IMA VSMC. However, high dose ox-LDL produced significant chemotaxis in CA VSMC that was inhibited by pravastatin (100 nM), mevastatin (10 nM), losartan (10 nM), enalapril (1 microM), and MnTBAP (a free radical scavenger, 50 microM). Microinjection experiments with isoprenoids i.e. geranylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP) showed distinct involvement of small GTPases in atherogen-induced VSMC migration. Significant increases in antioxidant enzyme activities and nitrite production along with marked decreases in NAD(P)H oxidase activity and O2- levels were determined in IMA versus CA VSMC.
Enhanced intrinsic antioxidant capacity may confer on IMA VSMC resistance to migration against atherogenic agents. Drugs that regulate ox-LDL or angiotensin II levels also exert antimigratory effects.
本研究调查了源自人冠状动脉(CA)和乳内动脉(IMA)的血管平滑肌细胞(VSMC)在致动脉粥样硬化诱导的迁移行为和基础抗氧化酶能力方面是否存在差异。
使用邓恩趋化室进行迁移实验。通过特定测定法测定促氧化剂[NAD(P)H氧化酶]和抗氧化剂[一氧化氮合酶、超氧化物歧化酶、过氧化氢酶和谷胱甘肽过氧化物酶]的酶活性。
趋化实验表明,虽然两组VSMC均向血小板衍生生长因子-BB(1 - 50 ng/ml)和血管紧张素II(1 - 50 nM)迁移,但氧化型低密度脂蛋白(ox-LDL,25 - 100 μg/ml)和天然低密度脂蛋白(100 μg/ml)均不影响IMA VSMC的趋化性。然而,高剂量ox-LDL在CA VSMC中产生显著趋化性,普伐他汀(100 nM)、美伐他汀(10 nM)、氯沙坦(10 nM)、依那普利(1 μM)和MnTBAP(一种自由基清除剂,50 μM)可抑制这种趋化性。用类异戊二烯即香叶基香叶基焦磷酸(GGPP)和法尼基焦磷酸(FPP)进行的显微注射实验表明,小GTP酶在致动脉粥样硬化诱导的VSMC迁移中明显参与。与CA VSMC相比,IMA VSMC中抗氧化酶活性和亚硝酸盐生成显著增加,同时NAD(P)H氧化酶活性和O2-水平显著降低。
增强的内在抗氧化能力可能使IMA VSMC对致动脉粥样硬化剂的迁移具有抗性。调节ox-LDL或血管紧张素II水平的药物也具有抗迁移作用。